Dr. Brian Windsor currently serves as President and Chief Executive Officer of Rein Therapeutics, a publicly traded biopharmaceutical company developing therapies for serious lung conditions. He started as the first employee in 2013 and took the company public through a merger in 2023. During the time at Rein, he spun out technology into a separate company, TFF Pharmaceuticals, and he took TFF public in October 2019. From September 2019 to March 2022, Dr. Windsor served on the TFF board of directors and also as the Chief Scientific Officer.

He has been involved in the startup, development, and funding of sixteen life science companies. He has authored numerous scientific publications, is listed as an inventor on multiple patents, and is a speaker at scientific and medical conferences.

Dr. Windsor earned his B.S. and Ph.D. in Molecular Biology from The University of Texas at Austin, where his work on mechanisms of multi-drug resistance resulted in patented technology. He currently serves as an advisor to Dell Medical School’s Office of Innovation and Entrepreneurship.